Pharmacist Perspectives: Exploring the Evolving Role of BTK Inhibitors in CLL

Activity Details
  • Credit Amounts:
    • CPE: 1.00
    • Other: 1.00
  • Cost: Free
  • Release: Apr 13, 2020
  • Expires: Apr 13, 2021
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Faculty

Emily Dotson Emily Dotson, PharmD, BCOP
Clinical Pharmacist Specialist–Hematology Lead
The Ohio State University
The James Cancer Hospital
Columbus, Ohio


Kathy Edwards Kathy Edwards, PharmD, BCPS, BCOP
Affiliate Associate Professor, College of Pharmacy
Medical University of South Carolina
Charleston, South Carolina

Needs Statement

Participants will gain exposure to emerging clinical and scientific advances in the treatment of chronic lymphocytic leukemia (CLL) with BTK inhibitors (BTKis), including novel pharmacologic targets within the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for BTK inhibitors in both treatment-naïve (TN) and relapsed/refractory (R/R) CLL. Prominent mechanisms of BTK inhibitor resistance and adaptive strategies used to prevent and/or mitigate the development of resistance also will be explored. Using a case-based approach, there is discussion focused on common clinical challenges, anticipation and management of adverse events, promotion of patient adherence, and optimization of outcomes for patients with CLL.

Accreditation

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This application-based activity is approved for 1.0 contact hour (0.01 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-014-H01-P).

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner

Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters

Kathy Hogan Edwards, PharmD, BCPS, BCOP—has disclosed that she is a consultant for Genzyme Corporation.

Emily K. Dotson, PharmD, BCOP—has disclosed that she is a consultant for AstraZeneca.

Content Reviewer

Bryan C. Taylor, PharmDhas no relevant financial relationships to disclose in relation to the content of this activity.

 

Activity Instructions

Media: Internet Web Activity (PowerPoint slides and audio)

Instructions:

To receive a statement of credit, you must:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Review the full content of the activity and reflect upon its teaching.
  3. Complete the questions and evaluation at the end of the activity.
  4. You must have a passing score of 80% on the post-test. You will have two (2) opportunities to complete the post-test.